



# GLAND PHARMA LIMITED

January 06, 2023

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex  
Bandra (East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as 'Listing Regulations')**

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on **Monday, 23<sup>rd</sup> January 2023**, *inter alia*, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022.

**Trading Window:**

In continuation to our earlier intimation dated December 30, 2022; this is to inform you that the trading window, which was closed from **Sunday, 1<sup>st</sup> January 2023** in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on **Thursday, 26<sup>th</sup> January 2023**.

**Earnings Call:**

The Company will hold an Investor/Analyst call on **Monday, 23<sup>rd</sup> January 2023 at 18:30 hours (IST)** to discuss the financial results and business outlook. Details of the call will be intimated to the stock exchanges and published on the Company's website ([www.glandpharma.com](http://www.glandpharma.com)) in due course.

This is for your information and records.

**Yours truly,  
For Gland Pharma Limited**

**P Sampath Kumar  
Company Secretary and Compliance Officer**